… to progress to castration-resistance is the key to developing future therapy. … castration
resistance, the agents currently available for treatment of CRPC, and the mechanisms of resistance …

… (CRPC) is an advanced form of prostate cancer characterised by disease progression …
deprivation) castration. The process by which prostate cancer cells become castrate resistant is …

… of care in men with symptomatic castration-resistant prostate cancer (CRPC). However, a …
and die of (or with) prostate cancer. Resistance to chemotherapy in metastatic CRPC is a result …

… Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of
treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic …

… Patients with castration-resistant prostate cancer (CRPC), who … the mechanisms of prostate
cancer resistance, possible … -refractory metastatic castration resistant prostatic cancer. In the …

Purpose : This Guideline is intended to provide a rational basis for the management of
patients with castration-resistant prostate cancer based on currently available published data. …

… pre-treated castration resistant prostate cancer (CRPC) [… metastatic castration resistant
prostate cancer (CRPC) after … symptomatic hormone-resistant prostate cancer: a Canadian …

… Great strides have been made in the treatment of localized prostate cancer, but the metastatic
disease and its progression to castration-resistant prostate cancer (CRPC) are commonly …

A subset of patients with advanced castration-resistant prostate cancer may eventually evolve
into an androgen receptor (AR)–independent phenotype, with a clinical picture associated …

… guidelines to summarise the optimal management of patients with prostate cancer and
rising prostate-specific antigen despite castrate testosterone levels, but with no evidence of …